Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch

This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6 :: RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clinical ame...

Full description

Saved in:
Bibliographic Details
Published inNPJ precision oncology Vol. 8; no. 1; pp. 167 - 6
Main Authors Deschler-Baier, Barbara, Krebs, Markus, Kroiss, Matthias, Chatterjee, Manik, Gundel, Daniel, Kestler, Christian, Kerscher, Alexander, Kunzmann, Volker, Appenzeller, Silke, Maurus, Katja, Rosenwald, Andreas, Bargou, Ralf, Gerhard-Hartmann, Elena, Venkataramani, Vivek
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 31.07.2024
Nature Publishing Group
Nature Portfolio
Subjects
692/308/409
692/308/53
Cancer Research
Case Report
Case reports
Gene Therapy
Human Genetics
Inhibitor drugs
Internal Medicine
Medicine
Medicine & Public Health
Neuroendocrine tumors
Oncology
Pancreatic cancer
Smartwatches
Wearable computers
Online AccessGet full text

Cover

More Information
Summary:This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6 :: RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clinical amelioration shortly after initiating selpercatinib within the LOXO-RET-17001 study (ClinicalTrials.gov ID: NCT03157128, first posted: 2017-05-17). Data from the patient’s smartwatch suggested early efficacy before conventional methods, such as serum tumor markers and CT imaging confirmed the antitumor activity. This case not only underscores the efficacy of selpercatinib in treating RET fusion-positive rare tumors but also highlights the potential of wearable technology in cancer care. In conclusion, the standard readings from commercially available wearable devices can be useful for the monitoring of treatment response to targeted therapy and may serve as digital biomarkers in clinical trials. This approach marks a significant advancement in patient-centric healthcare, leveraging technology to enhance the effectiveness and precision of treatment evaluation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-024-00659-x